$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc

$qprc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024043795 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$850.0K	$1.045M
YoY Change		416.05%
Cost Of Revenue	$318.0K
YoY Change
Gross Profit	$463.4K	$483.4K
YoY Change	-575.23%	3227.93%
Gross Profit Margin	54.51%	46.26%
Selling, General & Admin	$816.4K	$577.3K
YoY Change	25.62%	-25.79%
% of Gross Profit	176.2%	119.41%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$164.2K	$166.9K
YoY Change	-28.56%	5.04%
% of Gross Profit	35.44%	34.52%
Operating Expenses	$816.4K	$577.3K
YoY Change	25.62%	-25.79%
Operating Profit	-$353.1K	-$93.83K
YoY Change	-52.76%	-87.71%
Interest Expense	$10.99K	-$337.6K
YoY Change	-102.6%	131.18%
% of Operating Profit
Other Income/Expense, Net	$10.99K	-$337.6K
YoY Change	-102.6%	131.18%
Pretax Income	-$342.1K	-$431.4K
YoY Change	-70.75%	-52.56%
Income Tax	$105.0K
% Of Pretax Income
Net Earnings	-$447.1K	-$431.4K
YoY Change	-61.77%	-54.07%
Net Earnings / Revenue	-52.6%	-41.29%
Basic Earnings Per Share	-$0.08	-$0.08
Diluted Earnings Per Share	-$0.08	-$0.08
COMMON SHARES
Basic Shares Outstanding	5.332M shares	5.332M shares
Diluted Shares Outstanding	5.332M shares	5.332M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$136.8K	$770.7K
YoY Change	6.44%	507.28%
Cash & Equivalents	$136.8K	$770.7K
Short-Term Investments
Other Short-Term Assets	$83.64K	$84.07K
YoY Change	150.73%	369.19%
Inventory
Prepaid Expenses
Receivables	$758.3K	$3.989M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$978.7K	$4.844M
YoY Change	504.63%	3244.68%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$3.344M	$3.508M
YoY Change	-17.29%	-17.9%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.344M	$3.508M
YoY Change	-17.29%	-17.9%
TOTAL ASSETS
Total Short-Term Assets	$978.7K	$4.844M
Total Long-Term Assets	$3.344M	$3.508M
Total Assets	$4.322M	$8.352M
YoY Change	2.8%	89.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$538.7K	$1.999M
YoY Change	160.99%	1066.73%
Accrued Expenses	$878.7K	$1.233M
YoY Change	-29.96%	18.57%
Deferred Revenue
YoY Change
Short-Term Debt	$6.772M	$8.299M
YoY Change	-32.46%	-12.96%
Long-Term Debt Due	$2.797M	$2.797M
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$11.23M	$14.81M
YoY Change	-23.33%	8.12%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K
YoY Change	0.0%	0.0%
Other Long-Term Liabilities	$53.67K	$53.67K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$203.7K	$203.7K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.23M	$14.81M
Total Long-Term Liabilities	$203.7K	$203.7K
Total Liabilities	$11.43M	$15.01M
YoY Change	-23.01%	8.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.79M	-$24.34M
YoY Change	-12.4%	-10.27%
Common Stock	$160.00	$160.00
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.109M	-$6.662M
YoY Change
Total Liabilities & Shareholders Equity	$4.322M	$8.352M
YoY Change	2.8%	89.08%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$447.1K	-$431.4K
YoY Change	-61.77%	-54.07%
Depreciation, Depletion And Amortization	$164.2K	$166.9K
YoY Change	-28.56%	5.04%
Cash From Operating Activities	$892.8K	-$628.4K
YoY Change	-282.16%	3.39%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.527M	$835.6K
YoY Change	-410.48%	-78.81%
NET CHANGE
Cash From Operating Activities	892.8K	-$628.4K
Cash From Investing Activities	0.000
Cash From Financing Activities	-1.527M	$835.6K
Net Change In Cash	-633.9K	$207.2K
YoY Change	-39720.63%	470.75%
FREE CASH FLOW
Cash From Operating Activities	$892.8K	-$628.4K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	$892.8K	-$628.4K
YoY Change	-282.16%	-83.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5331973	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5331973	shares
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	33-18099-NY
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	QUEST PATENT RESEARCH CORPORATION
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2873662
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	411 Theodore Fremd Ave
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 206S
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rye
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10580-1411
CY2024Q1	dei	City Area Code CityAreaCode	(888)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	743-7577
CY2024Q1	dei	Security12b Title Security12bTitle	None
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5331973	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	770696	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	563484	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3989156	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3015295	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	84074	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	28121	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	4843926	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3606900	usd
CY2024Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	2579264	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	2412397	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3507736	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3674603	usd
CY2024Q1	us-gaap	Assets Assets	8351662	usd
CY2023Q4	us-gaap	Assets Assets	7281503	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1999416	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1674690	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8161151	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7325502	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	481231	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	281809	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	1232981	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1096985	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14809279	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13313486	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
CY2024Q1	qprc	Purchase Price Of Patents PurchasePriceOfPatents	53665	usd
CY2023Q4	qprc	Purchase Price Of Patents PurchasePriceOfPatents	53665	usd
CY2024Q1	us-gaap	Liabilities Liabilities	15012944	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13517151	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00003
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00003
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5331973	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5331973	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5331973	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5331973	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	160	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17680793	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17674985	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24342463	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23911021	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-6661510	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6235876	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	228	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6661282	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6235648	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8351662	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7281503	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1045000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202500	usd
CY2024Q1	qprc	Litigation And Licensing Expenses LitigationAndLicensingExpenses	561552	usd
CY2023Q1	qprc	Litigation And Licensing Expenses LitigationAndLicensingExpenses	187973	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	483448	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	14527	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	577279	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	777857	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	577279	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	777857	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-93831	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-763330	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	199422	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8566	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-138189	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-137469	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-337611	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-146035	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-431442	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-909365	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-431442	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-939365	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5331973	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5331973	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8562827	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18573	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-939365	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9483619	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6235648	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	5808	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-431442	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6661282	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-431442	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-939365	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	199422	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8566	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5808	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18573	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	166867	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	158872	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	973861	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	135996	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	135276	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	55953	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12598	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	324726	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	22841	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-628437	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-607835	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3300000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3300000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	835649	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	55860	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	835649	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3944140	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	207212	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	36305	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	563484	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90601	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	770696	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126906	usd
CY2024Q1	qprc	Interest Added To Principal InterestAddedToPrincipal	1402	usd
CY2023Q1	qprc	Interest Added To Principal InterestAddedToPrincipal	1387	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	2193	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2193	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3989000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3015000	usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit	3000000	usd
CY2024Q1	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Patent Licensing Fees</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers”. Revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Under Topic 606, revenue is recognized when there is a contract which has commercial substance which is approved by both parties and identifies the rights of the parties and the payment terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company’s operating subsidiaries as part of the settlement of litigation commenced by the Company’s subsidiaries. Intellectual property rights granted included the following, as applicable: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The intellectual property rights granted were perpetual in nature, extending until the legal expiration date of the related patents. The individual intellectual property rights are not accounted for as separate performance obligations, as (a) the nature of the promise, within the context of the contract, is to transfer combined items to which the promised intellectual property rights are inputs and (b) the Company’s promise to transfer each individual intellectual property right described above to the customer is not separately identifiable from other promises to transfer intellectual property rights in the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the promised intellectual property rights are not individually distinct, the Company combined each individual IP right in the contract into a bundle of IP rights that is distinct and accounted for all of the intellectual property rights promised in the contract as a single performance obligation. The intellectual property rights granted were “functional IP rights” that have significant standalone functionality. The Company’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. The Company’s subsidiaries have no further obligation with respect to the grant of intellectual property rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant (i.e., transfer of control) of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the intellectual property rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 30 to 90 days of execution of the contract. Contractual payments made by licensees are generally non-refundable. The Company does not have any significant payment terms, as payment is received shortly after goods are delivered or services are provided, therefore there is no significant financing component or consideration payable to the customer in these transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s revenue for the three months ended March 31, 2024 was generated from licenses pursuant to the settlement of patent infringement lawsuits in the TLL portfolio. Revenue for the three months ending March 31, 2023 was generated from licenses pursuant to the settlement of patent infringement lawsuits in the Tyche and STX portfolios.</p>
CY2024Q1	qprc	Reimbursement Costs Received ReimbursementCostsReceived	334000	usd
CY2023Q1	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	30000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced any such losses in these accounts.</p>
CY2024Q1	qprc	Dilutive Potential Common Shares DilutivePotentialCommonShares	962463	shares
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1135465	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3507736	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	138000	usd
CY2024Q1	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	24342000	usd
CY2024Q1	qprc	Working Capital workingCapital	9965000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6087000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6087000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2579264	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2412397	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3507736	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3674603	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P5Y3M14D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P5Y5M19D
CY2021Q1	qprc	Purchase Price PurchasePrice	350000	usd
CY2021Q1	qprc	Gross Proceeds GrossProceeds	350000	usd
CY2021Q1	qprc	Aggregate Amount AggregateAmount	93900	usd
CY2021Q2	qprc	Purchase Price PurchasePrice	250000	usd
CY2021Q4	qprc	Purchase Price PurchasePrice	550000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2022Q1	qprc	Purchase Price PurchasePrice	1060000	usd
CY2022Q3	qprc	Purchase Price PurchasePrice	92000	usd
CY2023Q1	qprc	Purchase Price PurchasePrice	3300000	usd
CY2023Q3	qprc	Purchase Price PurchasePrice	30000	usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	167000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	159000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	469487	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	540589	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	500064	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	464786	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	397345	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8161151	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7325502	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	4877000	usd
CY2023Q1	qprc	Operating Capital Advance OperatingCapitalAdvance	200000	usd
CY2024Q1	qprc	Requested And Received RequestedAndReceived	834000	usd
CY2024Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	3300000	usd
CY2024Q1	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	25000000	usd
CY2023Q1	qprc	Proceeds From Finance ProceedsFromFinance	3300000	usd
CY2024Q1	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2796500	usd
CY2015Q4	qprc	Purchase Agreement PurchaseAgreement	4672810	usd
CY2024Q1	qprc	Asset Acquired Description AssetAcquiredDescription	Under these MPAs, Intelligent Partners participates in the monetization proceeds the Company receives with respect to new patents after QFL has received its negotiated rate of return.
CY2024Q1	us-gaap	Notes Issued1 NotesIssued1	250000	usd
CY2024Q1	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2050-05-14
CY2024Q1	qprc	Deducted Loan Amount DeductedLoanAmount	100	usd
CY2024Q1	qprc	Loan Origination Cost LoanOriginationCost	1000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	53665	usd
CY2022	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	53665	usd
CY2020Q2	qprc	Acquisition Funding Amount AcquisitionFundingAmount	95000	usd
CY2024Q1	qprc	Funder Received FunderReceived	53665	usd
CY2021Q1	us-gaap	Shares Issued SharesIssued	962463	shares
CY2021Q1	qprc	Warrant Yield Percentage WarrantYieldPercentage	0.10	pure
CY2021Q1	qprc	Aggregate Number Of Outstanding Shares AggregateNumberOfOutstandingShares	0.10	pure
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	481000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	282000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	281809	usd
CY2024Q1	qprc	Gain On Subsequent Measurement GainOnSubsequentMeasurement	199422	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	481231	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.39
CY2023Q4	qprc	Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageGrantDateFairValue	1.2
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2000000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.39
CY2024Q1	qprc	Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageGrantDateFairValue	1.2
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1200000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.97
CY2024Q1	qprc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Options Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOptionsExercisable	1.2
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	962463	shares
CY2023Q4	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice	0.54
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y1M20D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	962463	shares
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePrice	0.54
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P6Y10M24D
CY2024Q1	qprc	Outstanding Share Capital Percentage OutstandingShareCapitalPercentage	0.10	pure
CY2023Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	228	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	228	usd
CY2024Q1	qprc	Patent Service Costs PatentServiceCosts	30000	usd
CY2023Q1	qprc	Patent Service Costs PatentServiceCosts	0	usd
CY2023Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	1379000	usd
CY2024Q1	qprc	Initial Annual Salary InitialAnnualSalary	252000	usd
CY2016Q3	qprc	Annual Bonus Compensation Equal Percentage AnnualBonusCompensationEqualPercentage	0.30	pure
CY2016Q3	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	500000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	334000	usd
CY2024Q1	qprc	Compensation Percentage CompensationPercentage	0.20	pure
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	qprc	Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Grant Date Fair Value Exercised ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageGrantDateFairValueExercised
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	qprc	Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Grant Date Fair Value Expired ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageGrantDateFairValueExpired
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	qprc	Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Grant Date Fair Value Cancelled ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageGrantDateFairValueCancelled
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceGranted
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedPeriod		shares
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpired		shares
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2024Q1	qprc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceCancelled
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000824416
CY2024Q1	dei	No Trading Symbol Flag NoTradingSymbolFlag	true

Files In Submission

Name	View Source	Status
0001213900-24-043795-index-headers.html	Edgar Link	pending
0001213900-24-043795-index.html	Edgar Link	pending
0001213900-24-043795.txt	Edgar Link	pending
0001213900-24-043795-xbrl.zip	Edgar Link	pending
ea0205721-10q_quest.htm	Edgar Link	pending
ea020572101ex31-1_quest.htm	Edgar Link	pending
ea020572101ex32-1_quest.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qprc-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
qprc-20240331_cal.xml	Edgar Link	unprocessable
qprc-20240331_def.xml	Edgar Link	unprocessable
ea0205721-10q_quest_htm.xml	Edgar Link	completed
qprc-20240331_pre.xml	Edgar Link	unprocessable
qprc-20240331_lab.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc

2024 Q2 Form 10-Q Financial Statement

#000121390024043795 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QPRC QUEST PATENT RESEARCH CORP Stock $qprc

2024 Q2 Form 10-Q Financial Statement

#000121390024043795 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QPRC
QUEST PATENT RESEARCH CORP Stock $qprc